BRIEF-GSK, Theravance say positive FF/VI phase III study to support filing in Japan
April 22, 2014 at 08:42 AM EDT
* GSK & Theravance announce phase III study of FF/VI in COPD commenced to support potential future filing in Japan
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.